|Chennai||Rs. 27770.00 (-0.14%)|
|Mumbai||Rs. 29200.00 (2.31%)|
|Delhi||Rs. 27900.00 (-0.36%)|
|Kolkata||Rs. 28270.00 (1%)|
|Kerala||Rs. 27050.00 (-0.37%)|
|Bangalore||Rs. 27550.00 (1.66%)|
|Hyderabad||Rs. 27770.00 (-0.14%)|
Kolkata, Feb 19 (IANS) Drugmaker Sanofi India, a unit of France's Sanofi, Tuesday said it may consider launching sub-brands of its well-known brands like Avil, Soframycin and Sea Cod in the future.
The firm has recently launched sub-brand Combiflam Plus in the market after launching pain relief cream Combiflam across India.
"This is the brand extension. We are first looking at our biggest brand Combiflam. This is the second time we extend the brand," said Sanofi India senior director (consumer healthcare) Anindya Chowdhury.
Chowdhury was in the city on the occasion of launching Combiflam Plus. The new product marks the company's foray into the OTC (over the counter) headache segment in the country.
The firm has brands like Avil, Soframycin and Sea Cod in the market. Avil is the second largest brand in its portfolio in consumer healthcare segment.
"Sea Cod is a very important brand for us and it is in the market for a very long time," Chowdhury said.
Asked whether the company would be looking to launch sub-brands of its popular other brands, he said: "We could look at that. Brand extension is one part of the strategy."
He said Sanofi was not looking at launching new brands very frequently.
The drugmaker said it was planning to double its market share in the country's consumer healthcare business to 4.2 percent in the next three years.